About Merrimack Pharmaceuticals (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.81%
Quick Ratio4.81%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$144.27 million
Price / Sales0.78
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book1.16
Profitability
EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-773.68%
Return on Assets-50.11%
Miscellaneous
Employees72
Outstanding Shares13,340,000
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Merrimack Pharmaceuticals's stock reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals (NASDAQ:MACK) posted its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, missing the consensus estimate of ($3.30) by $0.70. The biopharmaceutical company earned $33.70 million during the quarter, compared to the consensus estimate of $33.35 million. Merrimack Pharmaceuticals's revenue was up 58.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.30) EPS. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
2 analysts have issued 1-year target prices for Merrimack Pharmaceuticals' stock. Their predictions range from $12.00 to $12.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Sienna Biopharmaceuticals (SNNA), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), GTX (GTXI) and Dermira (DERM).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Ulrik B. Nielsen, Co-Founder & Director (Age 46)
- Dr. Richard Peters, CEO, Pres & Director (Age 55)
- Dr. Anthony J. Sinskey, Co-Founder and Scientific Advisor (Age 78)
- Dr. Gavin MacBeath Ph.D., Founder
- Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
Press coverage about MACK stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 0.16 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $8.40.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $113.28 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Merrimack Pharmaceuticals (NASDAQ:MACK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/7/2017 | Annual | $10.60 | | 5/30/2017 | 5/17/2017 | 5/26/2017 |
(Data available from 1/1/2013 forward)
Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.53%
Institutional Ownership Percentage: 54.16%
Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/15/2017 | Ulrik B Nielsen | Director | Sell | 7,896 | $14.23 | $112,360.08 | 22,781 |  |
| 9/14/2017 | Ulrik B Nielsen | Director | Sell | 100 | $14.20 | $1,420.00 | 22,781 | |
| 9/13/2017 | Ulrik B Nielsen | Director | Sell | 21,556 | $14.40 | $310,406.40 | 37,437 | |
| 9/11/2017 | Ulrik B Nielsen | Director | Sell | 14,756 | $14.46 | $213,371.76 | 37,437 | |
| 5/12/2017 | Daryl C Drummond | Insider | Sell | 4,097 | $3.72 | $15,240.84 | | |
| 7/25/2016 | Birgit M Schoeberl | Insider | Sell | 50,000 | $5.50 | $275,000.00 | 115,657 | |
| 3/17/2016 | Michael E Porter | Director | Buy | 5,000 | $7.20 | $36,000.00 | 754,448 | |
| 3/15/2016 | Michael E Porter | Director | Buy | 5,000 | $7.65 | $38,250.00 | 749,448 | |
| 3/8/2016 | Michael E Porter | Director | Buy | 10,000 | $7.09 | $70,900.00 | 744,448 | |
| 3/3/2016 | Michael E Porter | Director | Buy | 15,000 | $6.39 | $95,850.00 | 724,448 | |
| 3/1/2016 | Michael E Porter | Director | Buy | 20,000 | $6.11 | $122,200.00 | 709,448 | |
| 2/29/2016 | Vivian S Lee | Director | Buy | 35,000 | $5.50 | $192,500.00 | 65,000 | |
| 2/29/2016 | William M Mcclements | Insider | Buy | 2,000 | $5.72 | $11,440.00 | 14,072 | |
| 1/5/2016 | Edward J. Stewart | insider | Sell | 4,000 | $8.00 | $32,000.00 | 21,385 | |
| 12/1/2015 | Edward J. Stewart | insider | Sell | 5,000 | $9.33 | $46,650.00 | 21,385 | |
| 11/2/2015 | Edward J. Stewart | insider | Sell | 6,000 | $9.42 | $56,520.00 | 21,385 | |
| 10/16/2015 | Edward J. Stewart | insider | Sell | 1,000 | $10.00 | $10,000.00 | 21,385 | |
| 10/2/2015 | Edward J. Stewart | insider | Sell | 5,000 | $8.20 | $41,000.00 | 21,385 | |
| 9/1/2015 | Edward J. Stewart | insider | Sell | 6,000 | $9.88 | $59,280.00 | 21,385 | |
| 8/21/2015 | Michael E Porter | Director | Buy | 5,000 | $9.76 | $48,800.00 | 699,448 | |
| 8/17/2015 | Edward J. Stewart | insider | Sell | 6,000 | $10.49 | $62,940.00 | 21,385 | |
| 8/14/2015 | Michael E Porter | Director | Buy | 13,000 | $10.54 | $137,020.00 | | |
| 7/20/2015 | Ulrik B Nielsen | Director | Sell | 20,000 | $10.71 | $214,200.00 | | |
| 7/15/2015 | Edward J Stewart | Insider | Sell | 6,000 | $11.84 | $71,040.00 | | |
| 7/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $11.85 | $177,750.00 | | |
| 6/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $12.02 | $480,800.00 | | |
| 6/18/2015 | Edward J Stewart | Insider | Sell | 2,000 | $12.00 | $24,000.00 | | |
| 6/15/2015 | Edward J Stewart | Insider | Sell | 6,000 | $10.67 | $64,020.00 | | |
| 6/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $10.65 | $159,750.00 | | |
| 5/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $13.04 | $521,600.00 | | |
| 5/13/2015 | Michael E Porter | Director | Buy | 8,284 | $11.79 | $97,668.36 | | |
| 4/20/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $12.88 | $515,200.00 | | |
| 4/15/2015 | Edward J Stewart | SVP | Sell | 8,000 | $12.79 | $102,320.00 | | |
| 4/15/2015 | William A Sullivan | CFO | Sell | 15,000 | $12.87 | $193,050.00 | | |
| 4/13/2015 | Gordon J Fehr | Director | Sell | 20,000 | $13.00 | $260,000.00 | | |
| 3/24/2015 | Robert J Mulroy | CEO | Sell | 114,368 | $11.71 | $1,339,249.28 | | |
| 3/23/2015 | Robert J Mulroy | CEO | Sell | 10,400 | $11.69 | $121,576.00 | | |
| 3/20/2015 | Michael E Porter | Director | Buy | 5,000 | $11.77 | $58,850.00 | | |
| 3/19/2015 | Ulrik B Nielsen | Director | Sell | 40,000 | $11.97 | $478,800.00 | | |
| 3/19/2015 | William A Sullivan | CFO | Sell | 15,000 | $11.97 | $179,550.00 | | |
| 3/17/2015 | Birgit M Schoeberl | Insider | Sell | 42,234 | $12.00 | $506,808.00 | | |
| 3/17/2015 | Edward J Stewart | SVP | Sell | 8,000 | $11.95 | $95,600.00 | | |
| 3/17/2015 | Michael E Porter | Director | Buy | 1,190 | $11.77 | $14,006.30 | | |
| 3/16/2015 | Birgit M Schoeberl | Insider | Sell | 20,897 | $12.00 | $250,764.00 | | |
| 3/16/2015 | Edward J Stewart | SVP | Sell | 6,000 | $11.93 | $71,580.00 | | |
| 3/11/2015 | Michael E Porter | Director | Buy | 5,000 | $11.33 | $56,650.00 | | |
| 3/2/2015 | Michael E Porter | Director | Buy | 5,000 | $10.93 | $54,650.00 | | |
| 2/23/2015 | Ulrik B Nielsen | Director | Sell | 20,000 | $10.91 | $218,200.00 | | |
| 2/20/2015 | Robert J Mulroy | CEO | Sell | 150,000 | $10.94 | $1,641,000.00 | | |
| 1/15/2015 | Edward J Stewart | SVP | Sell | 6,000 | $11.19 | $67,140.00 | | |
| 12/24/2014 | William A Sullivan | CFO | Sell | 15,000 | $10.70 | $160,500.00 | | |
| 12/23/2014 | Vivian S Lee | Director | Buy | 20,000 | $10.23 | $204,600.00 | | |
| 12/18/2014 | Anthony J Sinskey | Director | Sell | 20,000 | $10.31 | $206,200.00 | | |
| 12/15/2014 | Edward J Stewart | SVP | Sell | 6,000 | $10.63 | $63,780.00 | | |
| 12/8/2014 | Robert J Mulroy | CEO | Sell | 200,000 | $9.84 | $1,968,000.00 | | |
| 12/2/2014 | Michael E Porter | Director | Buy | 8,000 | $8.71 | $69,680.00 | | |
| 11/21/2014 | Michael E Porter | Director | Buy | 11,909 | $8.87 | $105,632.83 | | |
| 11/18/2014 | Edward J Stewart | SVP | Sell | 5,000 | $8.55 | $42,750.00 | | |
| 11/14/2014 | Michael E Porter | Director | Buy | 5,000 | $8.29 | $41,450.00 | | |
| 11/13/2014 | Gary L Crocker | Director | Buy | 14,390 | $8.47 | $121,883.30 | | |
| 11/12/2014 | Michael E Porter | Director | Buy | 40,000 | $8.37 | $334,800.00 | | |
| 10/23/2014 | Edward J Stewart | SVP | Sell | 3,000 | $9.05 | $27,150.00 | | |
| 9/30/2014 | William A Sullivan | CFO | Sell | 105,282 | $8.61 | $906,478.02 | | |
| 9/29/2014 | William A Sullivan | CFO | Sell | 64,404 | $8.40 | $540,993.60 | | |
| 9/24/2014 | Edward J Stewart | SVP | Sell | 12,000 | $8.22 | $98,640.00 | | |
| 6/23/2014 | Gary L Crocker | Director | Buy | 36,000 | $6.84 | $246,240.00 | | |
| 5/20/2014 | Gary Crocker | Director | Buy | 4,000 | $6.69 | $26,760.00 | 2,808,571 | |
| 5/19/2014 | Gary Crocker | Director | Buy | 9,400 | $6.68 | $62,792.00 | 2,804,571 | |
| 5/16/2014 | Michael Porter | Director | Buy | 15,000 | $6.49 | $97,350.00 | 535,865 | |
| 5/13/2014 | Anthony Sinskey | Director | Buy | 5,000 | $6.74 | $33,700.00 | | |
| 5/8/2014 | Michael Porter | Director | Buy | 10,000 | $6.59 | $65,900.00 | 520,865 | |
| 5/7/2014 | Gary Crocker | Director | Buy | 4,400 | $6.77 | $29,788.00 | | |
| 5/6/2014 | Gary Crocker | Director | Buy | 17,500 | $6.89 | $120,575.00 | 2,783,271 | |
| 5/5/2014 | Michael Porter | Director | Buy | 15,000 | $6.41 | $96,150.00 | 485,865 | |
| 5/5/2014 | Robert Mulroy | CEO | Buy | 5,000 | $6.31 | $31,550.00 | 946,069 | |
| 12/17/2013 | Michael Porter | Director | Buy | 25,000 | $4.75 | $118,750.00 | 470,865 | |
| 12/12/2013 | William Mcclements | SVP | Buy | 4,000 | $4.26 | $17,040.00 | 13,000 | |
| 12/10/2013 | Michael Porter | Director | Buy | 18,000 | $4.38 | $78,840.00 | 445,865 | |
| 12/6/2013 | James Quigley | Director | Buy | 39,000 | $4.70 | $183,300.00 | 51,500 | |
| 12/4/2013 | Robert Mulroy | CEO | Buy | 33,100 | $4.42 | $146,302.00 | 989,644 | |
| 12/3/2013 | Sarah Nash | Director | Buy | 47,500 | $4.17 | $198,075.00 | 976,994 | |
| 12/2/2013 | William Mcclements | SVP | Buy | 2,000 | $4.06 | $8,120.00 | 9,000 | |
| 11/29/2013 | Anthony Sinskey | Director | Buy | 3,800 | $3.92 | $14,896.00 | 392,543 | |
| 11/27/2013 | Gary Crocker | Director | Buy | 207,000 | $3.72 | $770,040.00 | | |
| 12/14/2012 | John Mendelsohn | Director | Buy | 5,000 | $6.63 | $33,150.00 | | |
| 12/13/2012 | Gary L Crocker | Director | Buy | 36,500 | $6.77 | $247,105.00 | | |
| 12/10/2012 | Michael E Porter | Director | Buy | 10,000 | $6.08 | $60,800.00 | | |
| 9/14/2012 | Gary L Crocker | Director | Buy | 64,800 | $8.33 | $539,784.00 | | |
| 8/24/2012 | James H Quigley | Director | Buy | 12,500 | $7.55 | $94,375.00 | | |
(Data available from 1/1/2013 forward)
Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Merrimack Pharmaceuticals Potential Catalyst A Likely Bust
seekingalpha.com - April 19 at 5:40 PM |
 | Zacks: Analysts Anticipate Merrimack Pharmaceuticals (MACK) to Announce -$1.28 EPS
www.americanbankingnews.com - April 13 at 7:15 PM |
 | Merrimack Pharma (MACK) to Present Preclinical Data at AACR Meeting
www.streetinsider.com - April 10 at 8:27 AM |
 | Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 8:19 AM |
| ValuEngine Downgrades Merrimack Pharmaceuticals (MACK) to Strong Sell
www.americanbankingnews.com - April 8 at 11:48 AM |
| Merrimack Pharmaceuticals (MACK) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM |
| Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - April 4 at 8:21 AM |
| Zacks: Analysts Anticipate Merrimack Pharmaceuticals Inc (MACK) to Announce -$1.28 EPS
www.americanbankingnews.com - March 27 at 7:18 PM |
| Merrimack Pharmaceuticals (MACK) Earns Hold Rating from Robert W. Baird
www.americanbankingnews.com - March 15 at 3:02 PM |
 | Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 14 at 8:33 AM |
 | Merrimack Provides Business Update and Reports 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 8:26 AM |
 | BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
www.reuters.com - March 12 at 9:15 AM |
| Merrimack Provides Business Update and Reports 2017 Financial Results
finance.yahoo.com - March 12 at 9:15 AM |
| Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
finance.yahoo.com - March 12 at 9:15 AM |
| Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Quarterly Sales of $33.00 Million
www.americanbankingnews.com - March 12 at 5:22 AM |
| Reviewing Merrimack Pharmaceuticals (MACK) and GenVec (GNVC)
www.americanbankingnews.com - March 11 at 5:28 PM |
| Merrimack Pharmaceuticals (MACK) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 6 at 8:18 PM |
| Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:18 AM |
| Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
finance.yahoo.com - March 5 at 8:18 AM |
| Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal ... - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:19 AM |
| Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)?
finance.yahoo.com - February 27 at 8:19 AM |
| BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121
www.reuters.com - February 26 at 5:44 PM |
| Merrimack Pharma (MACK) Reports Dosing 1st Patient in Randomized Phase 2 Clinical Study of MM-121 - StreetInsider.com
www.streetinsider.com - February 26 at 8:17 AM |
| Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
finance.yahoo.com - February 26 at 8:17 AM |
| What's in the Cards for Merrimack (MACK) in Q4 Earnings? - Nasdaq
www.nasdaq.com - February 24 at 8:16 AM |
 | What's in the Cards for Merrimack (MACK) in Q4 Earnings?
www.msn.com - February 23 at 5:58 PM |
| What's in the Cards for Merrimack (MACK) in Q4 Earnings?
finance.yahoo.com - February 23 at 5:58 PM |
| Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) to Post -$0.28 EPS
www.americanbankingnews.com - February 21 at 7:10 PM |
| Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - PR Newswire (press release)
www.prnewswire.com - February 20 at 8:17 AM |
| Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
finance.yahoo.com - February 20 at 8:17 AM |
| Merrimack Pharmaceuticals (MACK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM |
| Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 9:19 AM |
| Merrimack Pharmaceuticals Inc (MACK) Expected to Post Quarterly Sales of $33.00 Million
www.americanbankingnews.com - February 6 at 3:52 AM |
| Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - February 4 at 7:08 PM |
| Need for radiation sickness drug a sign of scary times
www.msn.com - February 1 at 9:40 AM |
| Contrasting Prana Biotechnology (PRAN) & Merrimack Pharmaceuticals (MACK)
www.americanbankingnews.com - January 27 at 3:32 AM |
| -$0.28 Earnings Per Share Expected for Merrimack Pharmaceuticals Inc (MACK) This Quarter
www.americanbankingnews.com - January 18 at 9:34 PM |
| Merrimack to Present at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 5 at 4:59 PM |
| Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:36 AM |
| Merrimack Pharmaceuticals Inc (MACK) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - January 2 at 3:30 AM |
| Reviewing Merrimack Pharmaceuticals (MACK) & Its Peers
www.americanbankingnews.com - December 18 at 3:28 AM |
| Head to Head Contrast: Merrimack Pharmaceuticals (MACK) versus Its Peers
www.americanbankingnews.com - December 17 at 1:28 PM |
| Merrimack Pharmaceuticals, Inc. (MACK) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - December 16 at 11:28 AM |
| Merrimack Pharmaceuticals (MACK) versus Its Competitors Financial Contrast
www.americanbankingnews.com - December 15 at 9:30 PM |
| BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
www.reuters.com - December 15 at 5:46 PM |
| Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 10:22 AM |
| Merrimack Pharmaceuticals (MACK) & Its Peers Financial Survey
www.americanbankingnews.com - December 10 at 1:36 PM |
| $33.00 Million in Sales Expected for Merrimack Pharmaceuticals, Inc. (MACK) This Quarter
www.americanbankingnews.com - November 30 at 8:16 PM |
| Form 8-K MERRIMACK PHARMACEUTICAL For: Nov 26 - StreetInsider.com
www.streetinsider.com - November 30 at 5:08 PM |
| Merrimack Announces Appointment of George Demetri, M.D., to ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 5:08 PM |
Merrimack Pharmaceuticals (NASDAQ:MACK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Merrimack Pharmaceuticals (NASDAQ:MACK) Income Statement, Balance Sheet and Cash Flow Statement
Merrimack Pharmaceuticals (NASDAQ MACK) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
